The Excessive Daytime Sleepiness Market Is Expected To Progress At A CAGR of 6.77% In The 7MM During The Study Period (2019-32), Assesses DelveInsight

The Excessive Daytime Sleepiness market is expected to grow due to factors such as an increase in the patient population as the prevalence of underlying medical conditions rises, as well as the expected entry of emerging therapies such as FT218 (Sodium Oxybate) Extended-Release Oral Suspension, THN102, AXS-12 (Reboxetine), and some other products in the 7MM Excessive Daytime Sleepiness market.

LAS VEGAS, April 4, 2022 /PRNewswire/ -- DelveInsight's Excessive Daytime Sleepiness Market Insights report includes a comprehensive understanding of current treatment practices, Excessive Daytime Sleepiness emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Excessive Daytime Sleepiness Market

• As per DelveInsight analysis, the Excessive Daytime Sleepiness market size was USD 4,946 million in 2021, which is further expected to increase by 2032.
• As per DelveInsight's estimates, the total Excessive Daytime Sleepiness prevalent population in the 7MM was more than 6.8 million in 2021. 
• Key Excessive Daytime Sleepiness companies such as Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and others are currently working to develop new drugs for Excessive Daytime Sleepiness which can be available in the Excessive Daytime Sleepiness market in the upcoming years.
• The Excessive Daytime Sleepiness therapies in the pipeline include FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others.
• The increase in  the Excessive Daytime Sleepiness market size is a direct result of the anticipated approval of new Excessive Daytime Sleepiness medication and the growing patient population in the 7MM.

Discover more about therapies set to grab major Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness Market Landscape

Excessive Daytime Sleepiness Overview

Excessive Daytime Sleepiness (EDS) is defined as a problem staying awake and aware during the day's major waking episodes, with sleep happening accidentally or at inappropriate periods of the wake period. As a result, a lack of quality sleep can cause a  number of Excessive Daytime Sleepiness symptoms. The most common Excessive Daytime Sleepiness symptoms are feelings of irritation, memory problems, difficulty in making decisions, slower reaction times, risk-taking behaviors, trouble in staying alert, trouble focusing, and others.

The most prevalent Excessive Daytime Sleepiness causes are sleep deprivation, obstructive sleep apnea, and sedating drugs. Other probable Excessive Daytime Sleepiness causes include medical and mental conditions such as Parkinson's disease (PD) and Bipolar Disorder, as well as sleep disorders such as narcolepsy.

The Excessive Daytime Sleepiness diagnosis includes questionnaires, identification of underlying medical conditions, and diagnostic Excessive Daytime Sleepiness tests [i.e., Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and Maintenance of Wakefulness Test (MWT)].

Excessive Daytime Sleepiness Epidemiology Segmentation

As per DelveInsight, the total Excessive Daytime Sleepiness diagnosed prevalent population in the 7MM was approx 6.8 million in 2021.

Among EU5 countries, Germany had the highest diagnosed prevalent population of Excessive Daytime Sleepiness in 2021.

The Excessive Daytime Sleepiness Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Total diagnosed prevalent cases of Excessive Daytime Sleepiness
• Total diagnosed prevalent cases of Excessive Daytime Sleepiness in different disorders

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiological Insights

Excessive Daytime Sleepiness Market

Excessive Daytime Sleepiness can be treated non pharmacologically or pharmacologically. The Excessive Daytime Sleepiness treatment is dependent on the underlying problem. Nonpharmacologic therapy (i.e., behavioral change such as regular sleeping and work adjustments) are frequently beneficial.

There are a few drugs approved in the 7MM for the Excessive Daytime Sleepiness treatment, including Provigil/Modiodal (modafinil), Nuvigil (armodafinil), Sunosi (solriamfetol), Wakix (Pitolisant), Xywav (calcium, magnesium, potassium, and sodium oxybates), and Xyrem (sodium oxybate). Generics for Provigil/Modiodal (modafinil) and Nuvigil (armodafinil) are available in the US market.

The Excessive Daytime Sleepiness market is very competitive, with many therapies approaching the market. The Excessive Daytime Sleepiness market is undergoing quick and significant change as research aims to give a greater understanding of rare neurological disorders such as Narcolepsy, Obstructive Sleep Apnea, Idiopathic Hypersomnia, and others, and as novel therapeutics are being developed.

Discover more about therapy set to grab substantial Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness Treatment 

Excessive Daytime Sleepiness Pipeline Therapies and Key Players

• FT218: Avadel Pharmaceutical
• AXS-12: Axsome Therapeutic
• THN102: Theranexus
• Samelisant: Suven Life Sciences
• Quilience: NLS Pharma
• XW10172: XWPharma 
• TAK-994: Takeda

To know about more new drugs for Excessive Daytime Sleepiness treatment visit @ Excessive Daytime Sleepiness Medication 

Excessive Daytime Sleepiness Market Dynamics

The dynamics of the Excessive Daytime Sleepiness market is anticipated to change in the coming years owing to the rise in the prevalence of associated conditions such as Parkinson's disease, Obstructive Sleep Apnea, Narcolepsy, and others might contribute to an increase in the patient population of Excessive Daytime Sleepiness. Moreover, the green flag for Ozawade (pitolisant) in Europe and acceptance of IND application in the US for idiopathic hypersomnia will further strengthen the Excessive Daytime Sleepiness market. In addition, to the rising prevalence, the support of the US FDA by granting designations will also contribute to the Excessive Daytime Sleepiness market growth. Furthermore, most of the approved therapies are developed for daily intake. Hence medications with longer effectiveness are the current unmet need of the Excessive Daytime Sleepiness market. Moreover, several emerging drugs with novel mechanisms are being evaluated in clinical trials, making the current pipeline rich with new molecules and new formulations of existing therapies. Thus, the expected launch of drugs in the pipeline will fuel the Excessive Daytime Sleepiness market size. 

However, the high cost of therapies, low level of disease awareness and lack of understanding of the clinical course and clinical relevance may cause delay in Excessive Daytime Sleepiness diagnosis which will eventually hinder the Excessive Daytime Sleepiness market growth. Furthermore, the lack of practical measurement tools for Excessive Daytime Sleepiness diagnosis might also serve as a potential barrier to the Excessive Daytime Sleepiness market. Moreover, a low level of disease awareness as some associated diseases are not addressed yet, such as bipolar disorder might hamper the growth of the Excessive Daytime Sleepiness market. In addition, both marketed as well as emerging drugs are highly impacted by COVID-19. If the situation worsens, it will hamper the approval of upcoming products. On the other hand, the generic version of Xyrem and Sunosi are expected to reach the market in 2023 and 2026, respectively which will impact the Excessive Daytime Sleepiness market significantly in the future.

Scope of the Excessive Daytime Sleepiness Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Excessive Daytime Sleepiness Companies: Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and others
• Key Pipeline Therapies: FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others
• Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and emerging therapies
• Excessive Daytime Sleepiness Market Dynamics:  Excessive Daytime Sleepiness market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Excessive Daytime Sleepiness Market Access and Reimbursement

Discover more about the future Excessive Daytime Sleepiness market share of treatment therapies @ Medication for Excessive Daytime Sleepiness Treatment

Table of Contents

Get in touch with our Business executive @ Healthcare Due Diligence Services 

Related Reports

Excessive Daytime Sleepiness Epidemiology

Excessive Daytime Sleepiness Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Excessive Daytime Sleepiness epidemiology in the 7MM.

Excessive Daytime Sleepiness Pipeline

Excessive Daytime Sleepiness Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Excessive Daytime Sleepiness companies involved such as Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, among others.

Bipolar Disorder Market

Bipolar Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Bipolar Disorder companies such as Intra-Cellular Therapies, Sunovion Pharmaceuticals, COMPASS Pathways, Lundbeck, among others.

Narcolepsy Market

Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Narcolepsy companies such as Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, among others.

Sleep Apnea Market

Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Sleep Apnea companies such as Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, among others.

Sleep Apnea Implants Market

Sleep Apnea Implants Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Sleep Apnea Implants companies such as Inspire Medical Systems, LinguaFlex, LivaNova PLC, Medtronic, Respicardia Inc., among others.

Other Trending Reports

Diabetes Insipidus Market

Diabetes Insipidus Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Diabetes Insipidus companies such as Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, among others.

Erectile Dysfunction Market

Erectile Dysfunction Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Erectile Dysfunction companies such as Sumitovant Biopharma, Ildong Pharmaceutical, Aquestive Therapeutics, among others. 

Erectile Dysfunction Devices Market

Erectile Dysfunction Devices Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Erectile Dysfunction Devices companies such as Coloplast Corporation, Zimmer Aesthetics, Augusta Medical Systems, Medispec Ltd., MTS Medical UG, among others.

Renal Vasculitis Market

Renal Vasculitis Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Renal Vasculitis companies operating in the domain.

Childhood Atropine For Myopia Progression Market

Childhood Atropine For Myopia Progression Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key Childhood Atropine For Myopia Progression companies operating in the domain.

Syncope Market

Syncope Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Syncope companies such as Ottawa Hospital Research Institute, University of Alberta, CES University, among others.

Related Healthcare Blogs

Types of Sleep Disorders

Narcolepsy Treatment Market

Bipolar Depression Pipeline Therapies

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg